Obinutuzumab for primary membranous nephropathy (ORION)

Phase 2, open-label trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Incidence of complete or partial remission of nephrotic syndrome at 12 months and Incidence of serious and non-serious adverse events. Started Oct 2024; status: completed.